Enanta Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Enanta Pharmaceuticals

08/05/2023 22:01

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.79​​ per share for the quarter ended in
March. The mean expectation of eight analysts for the quarter
was for a loss of $1.98 per share.
    * Revenue fell 4.9% to $17.80 million from a year ago;
analysts
expected $19.18 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.79​.
    * The mean earnings estimate of analysts had risen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Enanta Pharmaceuticals Inc shares had fallen by 10.9% this
quarter and lost 22.6% so far this year.
    * The company reported a quarterly loss of $37.66 million.
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $68.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.98          -1.79          Beat
 Dec. 31 2022      -1.59          -1.39          Beat
 Sep. 30 2022      -1.35          -1.27          Beat
 Jun. 30 2022      -1.39          -1.53          Missed